Growing prevalence of various blood diseases such as anemia, myeloma, leukemia and sickle cell anemia has led the hematologists to focus on various detection processes. As demand for comparatively conducting comparatively short diagnosis process is becoming the need of the hour, hematologists are looking for better treatment processes through accurate diagnosis process. With the growing need to detect various blood conditions has further propelled hematologists to focus on enhancing their diagnostic skills. In order to develop successful treatment techniques, hematologist are significantly focusing on early diagnosis of the various hematologist diseases. Bound to these factors, growth of the global hematologist disease treatment market will continue to gain momentum during the forecast period.
According to Transparency Market Research, the global rare hematology market is expected to represent a value of over US$ 16,000 Mn by the end of 2022.
With growing prevalence of blood disorders and bleeding, demand for the recombinant factors continue to increase. On the basis of treatment type, the recombinant factors segment is expected to generate significant revenues, accounting for a value of over US$ 4,000 Mn by the end of 2022. On the other hand, the plasma derived factors treatment type segment is expected to register a robust CAGR throughout the forecast period. Based on age, the adults segment is expected to represent the highest growth in terms of revenue, recording a value of over US$ 3,000 Mn by the end 2017. However, the pediatric age segment is expected to represent the highest CAGR in the global market through 2022.
Request for the Report Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=34736
Leading market players operating in the global rare hematology market include Shire plc, Biogen Inc., Novo Nordisk A/S, Bayer Healthcare AG, CSL Behring LLC, Pfizer Inc., PRA Health Sciences, Celgene Corporation, Alexion Pharmaceuticals, Inc. and Amgen Inc.